Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations

<i>Background and Objective</i>: Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (<i>EGFR</i>) mutations show a good response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The subsequent treatments influence t...

Full description

Bibliographic Details
Main Authors: Hisao Imai, Ryoichi Onozato, Maiko Ginnan, Daijiro Kobayashi, Kyoichi Kaira, Koichi Minato
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/57/5/508
id doaj-62bd279f020449e0829927cb1acb4204
record_format Article
spelling doaj-62bd279f020449e0829927cb1acb42042021-06-01T00:27:21ZengMDPI AGMedicina1010-660X1648-91442021-05-015750850810.3390/medicina57050508Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> MutationsHisao Imai0Ryoichi Onozato1Maiko Ginnan2Daijiro Kobayashi3Kyoichi Kaira4Koichi Minato5Gunma Prefectural Cancer Center, Division of Respiratory Medicine, Ota, Gunma 373-8550, JapanGunma Prefectural Cancer Center, Division of Thoracic Surgery, Ota, Gunma 373-8550, JapanGunma Prefectural Cancer Center, Division of Pharmacy, Ota, Gunma 373-8550, JapanGunma Prefectural Cancer Center, Division of Radiation Oncology, Ota, Gunma 373-8550, JapanComprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, Hidaka, Saitama 350-1298, JapanGunma Prefectural Cancer Center, Division of Respiratory Medicine, Ota, Gunma 373-8550, Japan<i>Background and Objective</i>: Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (<i>EGFR</i>) mutations show a good response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The subsequent treatments influence the evaluability of the efficacy of front-line therapy on overall survival (OS). Consequently, we evaluated the associations of relapse-free survival (RFS) and post-progression survival (PPS) with OS in patients who exhibited postoperative relapse of <i>EGFR</i>-mutated NSCLC. <i>Materials and Methods</i>: We analyzed the data of 35 patients with <i>EGFR</i>-mutated NSCLC who underwent complete resection between January 2007 and June 2019. The correlations of RFS and PPS with OS were evaluated at the individual patient level. <i>Results:</i> Linear regression and Spearman’s rank correlation analyses demonstrated that the PPS highly correlated with OS (<i>r</i> = 0.91, <i>p</i> < 0.05, <i>R</i><sup>2</sup> = 0.85), whereas the RFS weakly associated with OS (<i>r</i> = 0.36, <i>p</i> < 0.05, <i>R</i><sup>2</sup> = 0.25). Age and performance status at relapse were significantly associated with PPS. <i>Conclusion</i>: Overall, PPS was more strongly and significantly associated with OS than RFS. These results suggest that the OS of our cohort may be affected by treatments, besides postoperative relapse. However, larger-scale prospective studies are needed to confirm these results.https://www.mdpi.com/1648-9144/57/5/508EGFR-TKI<i>EGFR</i> mutationnon-small-cell lung canceroverall survivalpostoperative relapsepost-progression survival
collection DOAJ
language English
format Article
sources DOAJ
author Hisao Imai
Ryoichi Onozato
Maiko Ginnan
Daijiro Kobayashi
Kyoichi Kaira
Koichi Minato
spellingShingle Hisao Imai
Ryoichi Onozato
Maiko Ginnan
Daijiro Kobayashi
Kyoichi Kaira
Koichi Minato
Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
Medicina
EGFR-TKI
<i>EGFR</i> mutation
non-small-cell lung cancer
overall survival
postoperative relapse
post-progression survival
author_facet Hisao Imai
Ryoichi Onozato
Maiko Ginnan
Daijiro Kobayashi
Kyoichi Kaira
Koichi Minato
author_sort Hisao Imai
title Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
title_short Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
title_full Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
title_fullStr Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
title_full_unstemmed Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
title_sort post-progression survival is strongly associated with overall survival in patients exhibiting postoperative relapse of non-small-cell lung cancer harboring sensitizing <i>egfr</i> mutations
publisher MDPI AG
series Medicina
issn 1010-660X
1648-9144
publishDate 2021-05-01
description <i>Background and Objective</i>: Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (<i>EGFR</i>) mutations show a good response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The subsequent treatments influence the evaluability of the efficacy of front-line therapy on overall survival (OS). Consequently, we evaluated the associations of relapse-free survival (RFS) and post-progression survival (PPS) with OS in patients who exhibited postoperative relapse of <i>EGFR</i>-mutated NSCLC. <i>Materials and Methods</i>: We analyzed the data of 35 patients with <i>EGFR</i>-mutated NSCLC who underwent complete resection between January 2007 and June 2019. The correlations of RFS and PPS with OS were evaluated at the individual patient level. <i>Results:</i> Linear regression and Spearman’s rank correlation analyses demonstrated that the PPS highly correlated with OS (<i>r</i> = 0.91, <i>p</i> < 0.05, <i>R</i><sup>2</sup> = 0.85), whereas the RFS weakly associated with OS (<i>r</i> = 0.36, <i>p</i> < 0.05, <i>R</i><sup>2</sup> = 0.25). Age and performance status at relapse were significantly associated with PPS. <i>Conclusion</i>: Overall, PPS was more strongly and significantly associated with OS than RFS. These results suggest that the OS of our cohort may be affected by treatments, besides postoperative relapse. However, larger-scale prospective studies are needed to confirm these results.
topic EGFR-TKI
<i>EGFR</i> mutation
non-small-cell lung cancer
overall survival
postoperative relapse
post-progression survival
url https://www.mdpi.com/1648-9144/57/5/508
work_keys_str_mv AT hisaoimai postprogressionsurvivalisstronglyassociatedwithoverallsurvivalinpatientsexhibitingpostoperativerelapseofnonsmallcelllungcancerharboringsensitizingiegfrimutations
AT ryoichionozato postprogressionsurvivalisstronglyassociatedwithoverallsurvivalinpatientsexhibitingpostoperativerelapseofnonsmallcelllungcancerharboringsensitizingiegfrimutations
AT maikoginnan postprogressionsurvivalisstronglyassociatedwithoverallsurvivalinpatientsexhibitingpostoperativerelapseofnonsmallcelllungcancerharboringsensitizingiegfrimutations
AT daijirokobayashi postprogressionsurvivalisstronglyassociatedwithoverallsurvivalinpatientsexhibitingpostoperativerelapseofnonsmallcelllungcancerharboringsensitizingiegfrimutations
AT kyoichikaira postprogressionsurvivalisstronglyassociatedwithoverallsurvivalinpatientsexhibitingpostoperativerelapseofnonsmallcelllungcancerharboringsensitizingiegfrimutations
AT koichiminato postprogressionsurvivalisstronglyassociatedwithoverallsurvivalinpatientsexhibitingpostoperativerelapseofnonsmallcelllungcancerharboringsensitizingiegfrimutations
_version_ 1721414855927267328